Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.

NCT03773367 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Resectable Gastric and Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Fluorouracil
DRUG: Oxaliplatin
DRUG: Irinotecan

Sponsor

Lund University Hospital